Jokath (Timolol, Travoprost)

Timolol reduces the production of aqueous humor by blocking β‑adrenergic receptors in the eye, while travoprost increases the outflow of fluid through the uveoscleral pathway as a prostaglandin analog. The dual mechanism results in a greater overall reduction of eye pressure than either agent alone.

The dosing regimen for Jokath is determined by the prescribing clinician based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) once daily, but exact instructions should always follow the prescriber’s order.

Safety data for Jokath in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss individual risks and benefits with the patient.

To request Jokath, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Jokath combines two mechanisms—beta‑blockade and prostaglandin‑mediated outflow enhancement—offering a broader pressure‑lowering effect than single‑agent drops such as timolol alone or prostaglandin analogs alone. This can simplify therapy for patients needing multiple agents, though individual response and tolerance vary.

Jokath should be stored at room temperature, below 25 °C, in its original container. Protect the bottle from moisture and direct sunlight. Do not freeze the solution, and keep the cap tightly closed when not in use.

Jokath is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the eye. Close the eye gently for a few minutes without blinking excessively, and avoid touching the tip of the bottle to any surface.

Serious risks include severe allergic reactions such as angio‑edema, worsening of asthma or COPD, systemic bradycardia or hypotension, and rare ocular complications like uveitis or corneal ulceration. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, rapid heartbeat, severe eye pain, or vision changes.

Jokath is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients in the formulation. It should also be avoided in individuals with severe sinus bradycardia, uncontrolled asthma, or active ocular infections without appropriate treatment.